Structural insights into the polypharmacological activity of quercetin on serine/threonine kinases

被引:16
作者
Baby, Bincy [1 ]
Antony, Priya [1 ]
Al Halabi, Walaa [1 ]
Al Homedi, Zahrah [1 ]
Vijayan, Ranjit [1 ]
机构
[1] United Arab Emirates Univ, Coll Sci, Dept Biol, POB 15551, Abu Dhabi, U Arab Emirates
关键词
serine/threonine kinases; quercetin; isoquercitrin; docking; polypharmacology; FLAVONOID QUERCETIN; STEM-CELLS; PROTEIN; CANCER; INHIBITOR; GROWTH; APOPTOSIS; BIOAVAILABILITY; ISOQUERCITRIN; INFORMATION;
D O I
10.2147/DDDT.S118423
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Polypharmacology, the discovery or design of drug molecules that can simultaneously interact with multiple targets, is gaining interest in contemporary drug discovery. Serine/threonine kinases are attractive targets for therapeutic intervention in oncology due to their role in cellular phosphorylation and altered expression in cancer. Quercetin, a naturally occurring flavonoid, inhibits multiple cancer cell lines and is used as an anticancer drug in Phase I clinical trial. Quercetin glycosides have also received some attention due to their high bioavailability and activity against various diseases including cancer. However, these have been studied to a lesser extent. In this study, the structural basis of the multitarget inhibitory activity of quercetin and isoquercitrin, a glycoside derivative, on serine/threonine kinases using molecular modeling was explored. Structural analysis showed that both quercetin and isoquercitrin exhibited good binding energies and interacted with aspartate in the highly conserved Asp-Phe-Gly motif. The results indicate that isoquercitrin could be a more potent inhibitor of several members of the serine/threonine kinase family. In summary, the current structural evaluation highlights the multitarget inhibitory property of quercetin and its potential to be a chemical platform for oncological polypharmacology.
引用
收藏
页码:3109 / 3123
页数:15
相关论文
共 58 条
[1]   IL-13-induced airway mucus production is attenuated by MAPK13 inhibition [J].
Alevy, Yael G. ;
Patel, Anand C. ;
Romero, Arthur G. ;
Patel, Dhara A. ;
Tucker, Jennifer ;
Roswit, William T. ;
Miller, Chantel A. ;
Heier, Richard F. ;
Byers, Derek E. ;
Brett, Tom J. ;
Holtzman, Michael J. .
JOURNAL OF CLINICAL INVESTIGATION, 2012, 122 (12) :4555-4568
[2]  
Angiolini M, 2011, FUTURE MED CHEM, V3, P309, DOI [10.4155/FMC.10.294, 10.4155/fmc.10.294]
[3]   Polypharmacology: Challenges and Opportunities in Drug Discovery [J].
Anighoro, Andrew ;
Bajorath, Juergen ;
Rastelli, Giulio .
JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (19) :7874-7887
[4]  
[Anonymous], 2014, Food Nutrit. Sci.
[5]  
[Anonymous], 2015, PRIM VERS 4 1
[6]  
[Anonymous], LIGPREP VERS 3 5
[7]  
Asaumi JI, 2000, ANTICANCER RES, V20, P2477
[8]   Oncogenic kinase signalling [J].
Blume-Jensen, P ;
Hunter, T .
NATURE, 2001, 411 (6835) :355-365
[9]   Quercetin inhibits a large panel of kinases implicated in cancer cell biology [J].
Boly, Rainatou ;
Gras, Thierry ;
Lamkami, Touria ;
Guissou, Pierre ;
Serteyn, Didier ;
Kiss, Robert ;
Dubois, Jacques .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2011, 38 (03) :833-842
[10]   Health effects of quercetin: From antioxidant to nutraceutical [J].
Boots, Agnes W. ;
Haenen, Guido R. M. M. ;
Bast, Aalt .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2008, 585 (2-3) :325-337